Patents by Inventor George L. Trainor

George L. Trainor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8633200
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: January 21, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Annapurna Pendri, Guo Li, Samuel Gerritz, David R. Langley, George L. Trainor, Nicholas A. Meanwell
  • Publication number: 20120225888
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: September 2, 2011
    Publication date: September 6, 2012
    Inventors: Annapurna Pendri, Guo Li, Samuel Gerritz, David R. Langley, George L. Trainor, Nicholas A. Meanwell
  • Publication number: 20100137319
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Application
    Filed: February 5, 2010
    Publication date: June 3, 2010
    Inventors: Harold Mastalerz, Dolatral M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • Publication number: 20090062288
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Application
    Filed: October 28, 2008
    Publication date: March 5, 2009
    Inventors: Harold Mastalerz, Dolatrai M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • Patent number: 7442700
    Abstract: The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: October 28, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Dolatrai M. Vyas, George L. Trainor, Ashvinikumar V. Gavai
  • Patent number: 7323587
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary incontinence; and type II diabetes, as well as, pharmaceutical compositions comprising at least one compound of the present invention.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: January 29, 2008
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 7045540
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 5-{2-[4-(1,2-Diphenyl-but-1-enyl)-phenyl]-vinyl}-1H-tetrazole, as selective estrogen receptor modulators. Also provided are methods for treating estrogen stimulated diseases in mammals including, but not limited to, for example, breast, uterine, ovarian, prostate and colon cancer; osteoporosis; endometriosis; uterine fibroid; Alzheimer's disease; macular degeneration; urinary incontinence; and type II diabetes, as well as, pharmaceutical compositions comprising at least one compound of the present invention.
    Type: Grant
    Filed: June 15, 2005
    Date of Patent: May 16, 2006
    Assignee: Bristol Meyers Squibb Company
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 6927224
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: August 9, 2005
    Assignee: Bristol Myers Squibb Company
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 6617310
    Abstract: This invention relates generally to phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions comprising the same, and methods of using the same for treating viral infection.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: September 9, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, George L. Trainor
  • Publication number: 20030105148
    Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: August 9, 2002
    Publication date: June 5, 2003
    Inventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
  • Patent number: 6528681
    Abstract: The present invention describes novel halogenated triphenylethylene derivatives, or pharmaceutically acceptable prodrug or salt forms thereof, as selective estrogen receptor modulators for the treatment of and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as methods for making the compounds and pharmaceutical compositions of this invention.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: March 4, 2003
    Assignee: Bristol-Meyers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, III, George L. Trainor
  • Patent number: 6391919
    Abstract: This invention relates generally to bis-amino acid sulfonamides containing substituted benzyl amines of formula I: or stereoisomeric forms, stereoisomeric mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as HIV protease inhibitors, pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as assay standards or reagents, and intermediates and processes for making the same.
    Type: Grant
    Filed: January 12, 2000
    Date of Patent: May 21, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert F. Kaltenbach, George L. Trainor
  • Publication number: 20020028791
    Abstract: This invention relates generally to phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines of formula I: 1
    Type: Application
    Filed: July 18, 2001
    Publication date: March 7, 2002
    Inventors: Robert F. Kaltenbach, George L. Trainor
  • Publication number: 20020013297
    Abstract: The present invention describes novel halogenated triphenylethylene derivatives, or pharmaceutically acceptable prodrug or salt forms thereof, as selective estrogen receptor modulators for the treatment of and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as methods for making the compounds and pharmaceutical compositions of this invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 31, 2002
    Inventors: Robert F. Kaltenbach III, George L. Trainor
  • Patent number: 5625081
    Abstract: Intermediates for fluorescent dyes based on 9-carboxyethyl-6-hydroxy-3-oxo-3H-xanthene which are useful as reporters for reporter-labeled DNA fragments are described. The intermediates are protected fluorescent dyes bearing acyloxy groups at the 3 and 9 positions and an alkoxy group at the 9 position. Deprotection of the protected fluorescent dye by treatment with aqueous ammonia regenerates free dye.
    Type: Grant
    Filed: January 13, 1994
    Date of Patent: April 29, 1997
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: George L. Trainor
  • Patent number: 5608063
    Abstract: A DNA sequencing system and method are described to detect the presence of radiant energy emitted from different excited reporter dye-labeled species (DNA fragments) following separation in time and/or space, and the identity of the species which emit radiant energy closely spaced in wavelength. Functions of the emitted energy are obtained which vary over the wavelengths of the closely spaced spectra in different senses and the functions ratioed, whereby the ratio is indicative of the identity of the DNA fragments.The emitting portion of the reporter-labeled DNA fragment is preferably one of a family of fluorescent dyes based on 9-carboxyethyl-6-hydroxy-3 -oxo-3H-xanthene. These xanthene dyes are covalently attached to the DNA fragments through the carboxylic acid functionality, preferably via an amide linkage. The dyes may be protected by including an alkoxy group at the 9-position. A spacer may be inserted between the dye and the amine.
    Type: Grant
    Filed: March 28, 1995
    Date of Patent: March 4, 1997
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Frank W. Hobbs, Jr., George L. Trainor
  • Patent number: 5558991
    Abstract: Acyclonucleoside triphosphates are described as being useful as chain terminators in DNA sequencing using a modification of the Sanger method.
    Type: Grant
    Filed: February 7, 1994
    Date of Patent: September 24, 1996
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: George L. Trainor
  • Patent number: 5470967
    Abstract: Oligonucleotides possessing at least one sulfamate or sulfamide internucleotides linkages. These compounds can be used as specific hybridization probes to detect complementary nucleic acid sequences.
    Type: Grant
    Filed: April 10, 1990
    Date of Patent: November 28, 1995
    Assignee: The Dupont Merck Pharmaceutical Company
    Inventors: Edward M. Huie, George L. Trainor
  • Patent number: 5332666
    Abstract: A DNA sequencing system and method are described to detect the presence of radiant energy emitted from different excited reporter dye-labeled species (DNA fragments) following separation in time and/or space, and the identity of the species which emit radiant energy closely spaced in wavelength. Functions of the emitted energy are obtained which vary over the wavelengths of the closely spaced spectra in different senses and the functions ratioed, whereby the ratio is indicative of the identity of the DNA fragments. The emitting portion of the reporter-labeled DNA fragment is preferably one of a family of fluorescent dyes based on 9-carboxyethyl-6-hydroxy-3-oxo-3H-xanthene. These xanthene dyes are covalently attached to the DNA fragments through the carboxylic acid functionality, preferably via an amide linkage. The dyes may be protected by including an alkoxy group at the 9-position. A spacer may be inserted between the dye and the amine.
    Type: Grant
    Filed: October 22, 1991
    Date of Patent: July 26, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: James M. Prober, Rudy J. Dam, Charles W. Robertson, Jr., Frank W. Hobbs, Jr., George L. Trainor
  • Patent number: 5306618
    Abstract: A DNA sequencing system and method are described to detect the presence of radiant energy emitted from different excited reporter dye-labeled species (DNA fragments) following separation in time and/or space, and the identity of the species which emit radiant energy closely spaced in wavelength. Functions of the emitted energy are obtained which vary over the wavelengths of the closely spaced spectra in different senses and the functions ratioed, whereby the ratio is indicative of the identity of the DNA fragments.The emitting portion of the reporter-labeled DNA fragment is preferably one of a family of fluorescent dyes based on 9-carboxyethyl-6-hydroxy-3-oxo-3H-xanthene. These xanthene dyes are covalently attached to the DNA fragments through the carboxylic acid functionality, preferably via an amide linkage. The dyes may be protected by including an alkoxy group at the 9-position. A spacer may be inserted between the dye and the amine.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: April 26, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: James M. Prober, Rudy J. Dam, Charles W. Robertson, Jr., Frank W. Hobbs, Jr., George L. Trainor